Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders

References

• Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed, Vol. 2. Lyon: IARC; 2008.
   Google Scholar
• Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012;13:196–206.
   PubMed Web of Science ®Google Scholar
• Zimmermann H, Trappe RU. Therapeutic options in post-transplant lymphoproliferative disorders. Ther Adv Hematol 2011;2:393–407.
   PubMedGoogle Scholar
• de Claro RA, McGinn K, Kwitkowski V, et al. U.S.Food and Drug Administration Approval Summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845–5849.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Sharman JP, Oki Y, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-Cell lymphomas. Blood 2013;122(Suppl. 1): Abstract 848.
   Google Scholar
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123:3095–3100.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma:results of a phase II study. J Clin Oncol 2012;30:2190–2196.
   PubMed Web of Science ®Google Scholar
• De Leval L, Gaulard P. CD30 + lymphoproliferative disorders. Haematologica 2010;95:1627–1630.
   PubMed Web of Science ®Google Scholar
• Hill BT, Tubbs Do RR, Smith MR. Complete remission of CD30 positive diffuse large b-cell lymphoma (DLBCL) in a Patient with post-transplant lymphoproliferative disorder (PTLD) and end-stage renal disease treated with single agent brentuximab vedotin. Leuk Lymphoma2014 Apr 9 . [Epub ahead of princt]
   Google Scholar
• Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol 2010;2:51–56.
   PubMedGoogle Scholar
• Gibson SE, Swerdlow SH, Craig FE, et al. EBV-positive extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in the posttransplant setting: a distinct type of posttransplant lymphoproliferative disorder?Am J Surg Pathol 2011;35:807–815.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Chao C, Silverberg MJ, Martínez-Maza O, et al. Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell lymphoma. Clin Cancer Res 2012;18:4702–4712.
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Boston R, Farrar JT, et al. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003;158:280–287.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013;121:2715–2724.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Wilson WH. EBV-associated lymphomas in adults. Best Pract Res Clin Haematol 2012;25:75–89.
   PubMed Web of Science ®Google Scholar
• Engel M, Essop MF, Close P, et al. Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases. J Clin Pathol 2000;53:182–186.
   PubMed Web of Science ®Google Scholar
• Keegan THM, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005;23:7604–7613.
   PubMed Web of Science ®Google Scholar
• Diepstra A, van Imhoff GW, Schaapveld M, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009;27:3815–3821.
   PubMed Web of Science ®Google Scholar
• Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:972–978.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117:3402–3408.
   PubMed Web of Science ®Google Scholar
• Pelzl S, Opelz G, Wiesel M, et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation2002 73:3–6.
   PubMed Web of Science ®Google Scholar
• Ciferská H, Horák P, Hermanová Z, et al. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol 2007;26:723–728.
   PubMed Web of Science ®Google Scholar
• Haque T, Chaggar T, Schafers J, et al. Soluble CD30:a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol 2011;83:311–316.
   PubMed Web of Science ®Google Scholar
• Visco C, Nadali G, Vassilakopoulos TP, et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 2006;77:387–394.
   PubMed Web of Science ®Google Scholar
• Richendollar BG, Tsao RE, Elson P, et al. Predictors of outcome in post-transplant lymphoproliferative disorder:an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leuk Lymphoma 2009;50:2005–2012.
   PubMed Web of Science ®Google Scholar
• Kinch A, Baecklund E, Backlin C, et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol 2014;53:669–679.
   PubMed Web of Science ®Google Scholar
• Johnson LR, Nalesnik MA, Swerdlow SH. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. Am J Surg Pathol 2006;30:1604–1612.
   PubMed Web of Science ®Google Scholar
• Lucioni M, Capello D, Riboni R, et al. B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients:clinical and molecular-histogenetic study of 17 cases from a single institution. Transplantation 2006;82:1013–1023.
   PubMed Web of Science ®Google Scholar
• Morscio J, Dierickx D, Ferreiro JF, et al. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant 2013;13:1305–1316.
   PubMed Web of Science ®Google Scholar